Drug-target residence time and its implications for lead optimization
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromolecules by low-molecular-mass drugs. The binding of drugs to their macromolecular targets is therefore seen as paramount for pharmacological activity. In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC(50) or K(d). This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex. We describe the potential advantages of long residence time in terms of duration of pharmacological effect and target selectivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The translation between slow inhibitor binding kinetics and sustained pharmacodynamic modulation has been studied for a numberoftarget classes (58).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [58]
In the citing paper
“Furthermore, the targets of infectious diseases usually have high replication rates, while covalent inhibitors tend to have long residence times making them less effective in this area [128].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [128]
In the citing paper
“Furthermore, longer residence times of drugs with their targets, as a result of slower off-rates, is a useful mechanism to extend in-vivo efficacy (59–61).”
From A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit (2026) · cites this paper as [59]
Citations
Cites
Catalysis in chemistry and enzymology
Jencks, W. P. (1969) · Medical Entomology and Zoology · Cited by 3,217
Structure and Mechanism in Protein Science
Fersht, A. (1998) · Cited by 1,882
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,122
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Self-citationLiang, J., Woodward, C., & Edelsbrunner, H. (1998) · Protein Science · doi:10.1002/pro.5560070905 · Cited by 1,057
Enzymes: a practical introduction to structure, mechanism, and data analysis
(2001) · Choice Reviews Online · doi:10.5860/choice.38-3881 · Cited by 1,056
Optical biosensors in drug discovery
Cooper, M. A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd838 · Cited by 1,015
Oppenheimer, N. J., & James, T. L. (1989) · Academic Press eBooks · Cited by 820
Rusnak, D. W., Lackey, K. E., Affleck, K., Wood, E. R., Alligood, K. J., Rhodes, N., Keith, B. R., Murray, D. M., Knight, W. B., Mullin, R. J., et al. (2001) · PubMed · Cited by 728
Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis
Copeland, R. A. (2000) · Wiley eBooks · doi:10.1002/0471220639 · Cited by 726
Self-citation
Cited by
Items 201–300 of 1,003
High-Throughput Screening for the Discovery of Enzyme Inhibitors
Lloyd, M. D. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00523 · Cited by 89
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients
Gampe, C. M., & Verma, V. A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01177 · Cited by 87
Ayaz, P., Andres, D., Kwiatkowski, D., Kolbe, C., Lienau, P., Siemeister, G., Lücking, U., & Stegmann, C. M. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00074 · Cited by 85
Antigen Potency and Maximal Efficacy Reveal a Mechanism of Efficient T Cell Activation
Dushek, O., Aleksic, M., Wheeler, R. J., Zhang, H., Cordoba, S., Peng, Y., Chen, J., Cerundolo, V., Dong, T., Coombs, D., et al. (2011) · Science Signaling · doi:10.1126/scisignal.2001430 · Cited by 83
McCoull, W., Abrams, R. D., Anderson, E., Blades, K., Barton, P., Box, M., Burgess, J., Byth, K., Cao, Q., Chuaqui, C., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00359 · Cited by 76
Proteus in the World of Proteins: Conformational Changes in Protein Kinases
Rabiller, M., Getlik, M., Klüter, S., Richters, A., Tückmantel, S., Simard, J. R., & Rauh, D. (2010) · Archiv der Pharmazie · doi:10.1002/ardp.201000028 · Cited by 78
Nagpal, I., Raj, I., Subbarao, N., & Gourinath, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030305 · Cited by 81
Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism
Vauquelin, G., Bostoen, S., Vanderheyden, P., & Seeman, P. M. (2012) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-012-0734-2 · Cited by 90
Role of water and steric constraints in the kinetics of cavity–ligand unbinding
Tiwary, P., Mondal, J., Morrone, J. A., & Berne, B. J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516652112 · Cited by 84
Temporal Bias: Time-Encoded Dynamic GPCR Signaling
Grundmann, M., & Kostenis, E. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.09.004 · Cited by 83
Biochemical Activity of Vaborbactam
Tsivkovski, R., & Lomovskaya, O. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01935-19 · Cited by 79
Structural basis of selective cannabinoid CB2 receptor activation
Li, X., Chang, H., Bouma, J., de Paus, L. V., Mukhopadhyay, P., Pálóczi, J., Mustafa, M. A., van der Horst, C., Kumar, S. S., Wu, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37112-9 · Cited by 84
Heinrich, T., Seenisamy, J., Emmanuvel, L., Kulkarni, S. S., Bomke, J., Rohdich, F., Greiner, H. E., Esdar, C., Krier, M., Grädler, U., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3016014 · Cited by 79
Rapid measurement of inhibitor binding kinetics by isothermal titration calorimetry
Trani, J. M. D., Cesco, S. D., O’Leary, R., Plescia, J., do Nascimento, C. J., Moitessier, N., & Mittermaier, A. (2018) · Nature Communications · doi:10.1038/s41467-018-03263-3 · Cited by 85
Predicting Residence Time and Drug Unbinding Pathway through Scaled Molecular Dynamics
Schuetz, D. A., Bernetti, M., Bertazzo, M., Müsil, D., Eggenweiler, H., Recanatini, M., Masetti, M., Ecker, G. F., & Cavalli, A. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00614 · Cited by 79
Incorporating Receptor Theory in Mechanism-Based Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling
Ploeger, B. A., van der Graaf, P. H., & Danhof, M. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.3 · Cited by 78
O’Connell, T. N., Ramsay, J., Rieth, S. F., Shapiro, M. J., & Stroh, J. G. (2014) · Analytical Chemistry · doi:10.1021/ac500938y · Cited by 78
Zhou, Y., Fu, Y., Yin, W., Li, J., Wang, W., Bai, F., Xu, S., Gong, Q., Peng, T., Yu, H., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01863 · Cited by 77
Predicting Biomolecular Binding Kinetics: A Review
Wang, J., Do, H. N., Koirala, K., & Miao, Y. (2023) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.2c01085 · Cited by 84
Ofori, L. O., Hoskins, J. W., Nakamori, M., Thornton, C. A., & Miller, B. L. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks298 · Cited by 77
Pearlstein, R. A., Hu, Q., Zhou, J., Yowe, D., Levell, J., Dale, B., Kaushik, V. K., Daniels, D., Hanrahan, S., Sherman, W., et al. (2010) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.22767 · Cited by 77
Role of Desolvation in Thermodynamics and Kinetics of Ligand Binding to a Kinase
Mondal, J., Friesner, R. A., & Berne, B. J. (2014) · Journal of Chemical Theory and Computation · doi:10.1021/ct500584n · Cited by 80
Designing Chimeric Molecules for Drug Discovery by Leveraging Chemical Biology
Borsari, C., Trader, D. J., Tait, A., & Costi, M. P. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01456 · Cited by 79
Flexible receptor docking for drug discovery
Wong, C. F. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1078308 · Cited by 81
Recent advances in dynamic docking for drug discovery
Vivo, M. D., & Cavalli, A. (2017) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1320 · Cited by 84
Design strategies to address kinetics of drug binding and residence time
Cusack, K. P., Wang, Y., Hoemann, M. Z., Marjanovic, J., Heym, R. G., & Vasudevan, A. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.02.027 · Cited by 80
Wang, Z., Cherukupalli, S., Xie, M., Wang, W., Jiang, X., Jia, R., Pannecouque, C. C., Clercq, E. D., Kang, D., Zhan, P., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01758 · Cited by 78
Towards Structural Systems Pharmacology to Study Complex Diseases and Personalized Medicine
Xie, L., Ge, X., Tan, H., Xie, L., Zhang, Y., Hart, T. D., Yang, X., & Bourne, P. E. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003554 · Cited by 81
Kinetic Solvent Viscosity Effects as Probes for Studying the Mechanisms of Enzyme Action
Gadda, G., & Sobrado, P. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00232 · Cited by 75
Quantifying Target Occupancy of Small Molecules Within Living Cells
Robers, M. B., Ohana, R. F., Huber, K., Kilpatrick, L. E., Vasta, J. D., Berger, B., Chaudhry, C., Hill, S. J., Müller, S., Knapp, S., et al. (2020) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-011420-092302 · Cited by 75
Sykes, D. A., & Charlton, S. J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01639.x · Cited by 74
Votapka, L. W., & Amaro, R. E. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004381 · Cited by 76
Guo, D. M., Heitman, L. H., & IJzerman, A. P. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00025 · Cited by 86
Bankar, G. R., Goodchild, S. J., Howard, S., Nelkenbrecher, K., Waldbrook, M., Dourado, M., Shuart, N. G., Lin, S., Young, C., Xie, Z., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.063 · Cited by 83
Systems Biology Brings New Dimensions for Structure-Based Drug Design
Pei, J., Yin, N., Ma, X., & Lai, L. (2014) · Journal of the American Chemical Society · doi:10.1021/ja504810z · Cited by 73
On-Demand Targeting: Investigating Biology with Proximity-Directed Chemistry
Long, M. J. C., Poganik, J. R., & Aye, Y. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b12608 · Cited by 75
Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery
Hallenbeck, K., Turner, D., Renslo, A., & Arkin, M. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160719163839 · Cited by 70
Ligand Residence Time at G-protein–Coupled Receptors—Why We Should Take Our Time To Study It
Hoffmann, C., Castro, M., Rinken, A., Leurs, R., Hill, S. J., & Vischer, H. F. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.099671 · Cited by 79
Drug profiling: knowing where it hits
Merino, A., Bronowska, A. K., Jackson, D., & Cahill, D. J. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.06.006 · Cited by 75
Li, H., Lai, C., Pan, P., Yu, W., Liu, N., Bommineni, G. R., García–Díaz, M., Simmerling, C. L., & Tonge, P. J. (2014) · ACS Chemical Biology · doi:10.1021/cb400896g · Cited by 75
Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics
Copeland, R. A., Moyer, M. P., & Richon, V. M. (2012) · Oncogene · doi:10.1038/onc.2012.552 · Cited by 75
Self-citationLindström, E., von Mentzer, B., Påhlman, I., Ahlstedt, I., Uvebrant, A., Kristensson, E., Martinsson, R., Novén, A., de Verdier, J., & Vauquelin, G. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.124958 · Cited by 71
Villacorta, L., Minarrieta, L., Salvatore, S. R., Khoo, N. K. H., Rom, O., Gao, Z., Berman, R. C., Jobbagy, S., Li, L., Woodcock, S. R., et al. (2018) · Redox Biology · doi:10.1016/j.redox.2018.01.005 · Cited by 73
Frequency adaptive metadynamics for the calculation of rare-event kinetics
Wang, Y., Valsson, Ó., Tiwary, P., Parrinello, M., & Lindorff‐Larsen, K. (2018) · The Journal of Chemical Physics · doi:10.1063/1.5024679 · Cited by 79
Use of Molecular Dynamics Simulations in Structure-Based Drug Discovery
Bera, I., & Payghan, P. V. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190903153043 · Cited by 76
Wang, Y., & Ma, S. (2013) · ChemMedChem · doi:10.1002/cmdc.201300209 · Cited by 70
Lamim Ribeiro, J. M., & Tiwary, P. (2019) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.8b00869 · Cited by 70
Can residence time offer a useful strategy to target agonist drugs for sustained GPCR responses?
Hothersall, J. D., Brown, A. J., Dale, I., & Rawlins, P. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.015 · Cited by 70
Binding Kinetics and Pathways of Ligands to GPCRs
Straßer, A., Wittmann, H., & Seifert, R. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.05.005 · Cited by 69
Hinchliffe, P., Tanner, C. A., Krismanich, A. P., Labbé, G., Goodfellow, V. J., Marrone, L., Desoky, A. Y., Calvopiña, K., Whittle, E. E., Zeng, F., et al. (2018) · Biochemistry · doi:10.1021/acs.biochem.7b01299 · Cited by 69
Lyczek, A., Berger, B.-T., Rangwala, A. M., Paung, Y., Tom, J., Philipose, H., Guo, J., Albanese, S. K., Robers, M. B., Knapp, S., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111451118 · Cited by 68
The Potential of Liposomal Drug Delivery for the Treatment of Inflammatory Arthritis
Vanniasinghe, A. S., Bender, V., & Manolios, N. (2008) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.08.004 · Cited by 80
Mechanical Modulation of Receptor-Ligand Interactions at Cell-Cell Interfaces
Allard, J. F., Dushek, O., Coombs, D., & van der Merwe, P. A. (2012) · Biophysical Journal · doi:10.1016/j.bpj.2012.02.006 · Cited by 69
From Drug Target to Leads-Sketching A Physicochemical Pathway for Lead Molecule Design In Silico
Shaikh, S. A., Jain, T., Sandhu, G., Latha, N., & Jayaram, B. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207782794220 · Cited by 78
Halogen–Aromatic π Interactions Modulate Inhibitor Residence Times
Heroven, C., Georgi, V., Ganotra, G. K., Brennan, P. E., Wolfreys, F. D., Wade, R. C., Fernández‐Montalván, A. E., Chaikuad, A., & Knapp, S. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201801666 · Cited by 68
Discovery of Potent and Selective Benzothiazole Hydrazone Inhibitors of Bcl-XL
Sleebs, B. E., Kersten, W. J. A., Kulasegaram, S., Nikolakopoulos, G., Hatzis, E., Moss, R. M., Parisot, J. P., Yang, H. J., Czabotar, P. E., Fairlie, W. D., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400556w · Cited by 72
Guo, D. M., van Dorp, E. J. H., Mulder‐Krieger, T., van Veldhoven, J. P. D., Brussee, J., IJzerman, A. P., & Heitman, L. H. (2012) · SLAS DISCOVERY · doi:10.1177/1087057112464776 · Cited by 77
Generalized Langevin Methods for Calculating Transmembrane Diffusivity
Gaalswyk, K., Awoonor‐Williams, E., & Rowley, C. N. (2016) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.6b00747 · Cited by 68
Persson, B. D., Müller, S., Reiter, D. M., Schmitt, B. B. T., Marttila, M., Sumowski, C. V., Schweizer, S., Scheu, U., Ochsenfeld, C., Arnberg, N., et al. (2008) · Journal of Virology · doi:10.1128/jvi.01967-08 · Cited by 67
Li, X. X., Lee, J. D., Massey, N. L., Guan, C. S., Robertson, A. A. B., Clark, R. J., & Woodruff, T. M. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114156 · Cited by 66
Ahmad, K., Rizzi, A., Capelli, R., Mandelli, D., Lyu, W., & Carloni, P. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.899805 · Cited by 74
Schnapp, G., Klein, T., Hoevels, Y., Bakker, R. A., & Nar, H. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00475 · Cited by 67
Munteanu, B., Meyer, B., von Reitzenstein, C., Burgermeister, E., Bog, S., Pahl, A., Ebert, M. P., & Hopf, C. (2014) · Analytical Chemistry · doi:10.1021/ac500038j · Cited by 66
Yang, Y., Lightstone, F. C., & Wong, S. E. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.749853 · Cited by 65
Li, X., Zuo, Y., Tang, G., Wang, Y., Zhou, Y., Wang, X., Guo, T., Xia, M., Ding, N., & Pan, Z. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4017762 · Cited by 63
Vilums, M., Zweemer, A. J. M., Yu, Z., de Vries, H., Hillger, J. M., Wapenaar, H., Bollen, I. A. E., Barmare, F., Gross, R. S., Clemens, J. J., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4011737 · Cited by 65
Cai, H., Rose, K., Liang, L.-H., Dunham, S. A., & Stover, C. K. (2008) · Analytical Biochemistry · doi:10.1016/j.ab.2008.10.041 · Cited by 65
Stoddart, L. A., Vernall, A. J., Bouzo-Lorenzo, M., Bosma, R., Kooistra, A. J., de Graaf, C., Vischer, H. F., Leurs, R., Briddon, S. J., Kellam, B., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19714-2 · Cited by 70
Zimmermann, G., Schultz-Fademrecht, C., Küchler, P., Murarka, S., Ismail, S., Triola, G., Nussbaumer, P., Wittinghofer, A., & Waldmann, H. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500632s · Cited by 62
Insight into the Inhibition of Drug‐Resistant Mutants of the Receptor Tyrosine Kinase EGFR
Engel, J., Becker, C., Lategahn, J., Keul, M., Ketzer, J., Mühlenberg, T., Kollipara, L., Schultz‐Fademrecht, C., Zahedi, R. P., Bauer, S., et al. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201605011 · Cited by 65
Spagnuolo, L. A., Eltschkner, S., Yu, W., Daryaee, F., Davoodi, S., Knudson, S. E., Allen, E. K. H., Merino, J., Pschibul, A., Moree, B., et al. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b11148 · Cited by 64
Uitdehaag, J. C. M., de Man, J., Willemsen‐Seegers, N., Prinsen, M. B. W., Libouban, M. A. A., Sterrenburg, J. G., de Wit, J. J. P., de Vetter, J. R. F., de Roos, J. A. D. M., Buijsman, R. C., et al. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.05.014 · Cited by 64
van der Velden, W. J. C., Heitman, L. H., & ROSENKILDE, M. M. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00012 · Cited by 66
Fleck, B. A., Hoare, S. R. J., Pick, R. R., BRADBURY, M. J., & Grigoriadis, D. E. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.188714 · Cited by 63
Ligand diffusion in proteins via enhanced sampling in molecular dynamics
Rydzewski, J., & Nowak, W. (2017) · Physics of Life Reviews · doi:10.1016/j.plrev.2017.03.003 · Cited by 67
Drug target residence time: a misleading concept
Folmer, R. H. A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.07.016 · Cited by 63
Molecular Mechanism of Action (MMoA) in Drug Discovery
Swinney, D. C. (2011) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-386009-5.00009-6 · Cited by 85
A universal homogeneous assay for high-throughput determination of binding kinetics
Schiele, F., Ayaz, P., & Fernández‐Montalván, A. E. (2014) · Analytical Biochemistry · doi:10.1016/j.ab.2014.09.007 · Cited by 62
The development of novel HIV integrase inhibitors and the problem of drug resistance
Wainberg, M. A., Mésplède, T., & Quashie, P. K. (2012) · Current Opinion in Virology · doi:10.1016/j.coviro.2012.08.007 · Cited by 71
Callegari, D., Lodola, A., Pala, D., Rivara, S., Mor, M., Rizzi, A., & Capelli, A. M. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00679 · Cited by 65
Juru, A. U., Patwardhan, N. N., & Hargrove, A. E. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.8b00945 · Cited by 64
Accuracy of Molecular Simulation-Based Predictions of k off Values: A Metadynamics Study
Capelli, R., Lyu, W., Bolnykh, V., Meloni, S., Olsen, J. M. H., Röthlisberger, U., Parrinello, M., & Carloni, P. (2020) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.0c00999 · Cited by 62
Swinney, D. C. (2008) · Pharmaceutical Medicine · doi:10.1007/bf03256679 · Cited by 79
Ritchie, T. J., Luscombe, C. N., & Macdonald, S. J. F. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci800429e · Cited by 62
Defining and characterizing drug/compound function
Kenakin, T., & Williams, M. J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.07.033 · Cited by 69
Evolution of the drug-target residence time model
Copeland, R. A. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1948997 · Cited by 61
Self-citationHow does a small molecule bind at a cryptic binding site?
Shan, Y., Mysore, V. P., Leffler, A. E., Kim, E. T., Sagawa, S., & Shaw, D. E. (2022) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1009817 · Cited by 60
Swinney, D. C., Beavis, P. A., Chuang, K., Zheng, Y., Lee, I., Gee, P., Deval, J., Rotstein, D. M., Dioszegi, M., Ravendran, P., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12683 · Cited by 61
Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer
Heuckmann, J. M., Rauh, D., & Thomas, R. K. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1825 · Cited by 62
Pearlstein, R. A., Sherman, W., & Abel, R. (2013) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24276 · Cited by 64
Real-time Characterization of Antibody Binding to Receptors on Living Immune Cells
Bondza, S., Foy, E., Brooks, J., Andersson, K., Robinson, J. I., Richalet-Sécordel, P. M., & Buijs, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00455 · Cited by 61
Lamb, K. N., Bsteh, D., Dishman, S. N., Moussa, H. F., Fan, H., Stuckey, J. I., Norris, J. L., Cholensky, S. H., Li, D., Wang, J., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.07.013 · Cited by 65
Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs
Rudolph, J., Roberts, G., & Luger, K. (2021) · Nature Communications · doi:10.1038/s41467-021-20998-8 · Cited by 67
Demystifying Functional Parameters for Irreversible Enzyme Inhibitors
Heppner, D. E., Ogboo, B. C., Urul, D. A., May, E. W., Schaefer, E., Murkin, A. S., & Gehringer, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01721 · Cited by 61
Rajagopalan, R., Misialek, S., Stevens, S., Myszka, D. G., Brandhuber, B. J., Ballard, J. A., Andrews, S. W., Seiwert, S. D., & Kossen, K. (2009) · Biochemistry · doi:10.1021/bi900038p · Cited by 61
García, I., Fall, Y., & Gómez, G. (2010) · Molecules · doi:10.3390/molecules15085408 · Cited by 60
Deng, L., Kitova, E. N., & Klassen, J. S. (2012) · Journal of the American Society for Mass Spectrometry · doi:10.1007/s13361-012-0533-5 · Cited by 60
Pan, P., Knudson, S. E., Bommineni, G. R., Li, H., Lai, C., Liu, N., García–Díaz, M., Simmerling, C. L., Patil, S. S., Slayden, R. A., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201300429 · Cited by 60
Koselny, K., Green, J., Favazzo, L., Glazier, V. E., DiDone, L., Ransford, S., & Krysan, D. J. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00134 · Cited by 61
Docking and Ligand Binding Affinity: Uses and Pitfalls
Yunta, M. J. R. (2016) · American Journal of Modeling and Optimization · doi:10.12691/ajmo-4-3-2 · Cited by 89
Metadata
- Authors
- Copeland, R. A., Pompliano, D. L., & Meek, T. D.
- Affiliations
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Copeland, Robert A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-08-04
- Volume
- 5
- Issue
- 9
- Pages
- 730-739
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2016408686
- Semantic Scholar
- 362824beb2008831aa65b4eb774e5c8703ff9c71
- Cited by
- 1,464
- References
- 46
- Citations by year
- 2026: 83 · 2025: 64 · 2024: 78 · 2023: 79 · 2022: 81 · 2021: 76 · 2020: 83 · 2019: 88 · 2018: 102 · 2017: 104 · 2016: 96 · 2015: 120 · 2014: 74 · 2013: 88 · 2012: 65
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Interaction Studies and Fluorescence Analysis
- Keywords
- drug-target residence time, lead optimization, drug selectivity, drug-target binding, binding affinity
- MeSH terms
- Binding, Competitive, Pharmaceutical Preparations, Humans, Kinetics, Ligands, Technology, Pharmaceutical, Drug Design, Drug Delivery Systems, Macromolecular Substances
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.